Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
114 Results for "
Hgf
" in MedChemExpress (MCE) Product Catalog:
Products (114)
114 Results for "Hgf" in MCE Product Catalog:
60
60 Publications Verification
Cat. No.: HY-P7044
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:
Human
Source:
E. coli
33
33 Cited Publications
Cat. No.: HY-P7063
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differentiation Factor; Interleukin BSF-2; Interleukin 6; Interferon Beta-2
Species:
Mouse
Source:
E. coli
6
6 Cited Publications
Cat. No.: HY-16969
CAS No.: 1401708-83-5
Synonyms: PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2
Target:
Research Areas:
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .
6
6 Cited Publications
Cat. No.: HY-P7121
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Hgf; Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor); Prev. DFNB39; Lung Fibroblast-Derived Mitogen; HPTA; Hepatopoietin-A; SF; Scatter Factor; F-TCF; Deafness, Autosomal Recessive 39; HgfB; Hepatopoietin A; Hepatocyte Growth Factor; Fibroblast-D
Species:
Human
Source:
CHO
5
5 Cited Publications
Cat. No.: HY-A0020
CAS No.: 104121-92-8
Synonyms: ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
Research Areas:
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
4
4 Cited Publications
Cat. No.: HY-P7103A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:
Rat
Source:
HEK293
3
3 Cited Publications
Cat. No.: HY-18696
CAS No.: 1173699-31-4
Target:
Research Areas:
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .
2
Target:
Research Areas:
2
2 Cited Publications
Target:
PF-04217903 is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) .
2
2 Cited Publications
Target:
Research Areas:
SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer .
2
2 Cited Publications
Target:
PF-04217903 mesylate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 mesylate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 mesylate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 mesylate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 mesylate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 mesylate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) .
2
2 Cited Publications
Cat. No.: HY-P70627
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Hgf; Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor); Prev. DFNB39; Lung Fibroblast-Derived Mitogen; HPTA; Hepatopoietin-A; SF; Scatter Factor; F-TCF; Deafness, Autosomal Recessive 39; HgfB; Hepatopoietin A; Hepatocyte Growth Factor; Fibroblast-Derived Tumor Cytotoxic Factor
Species:
Human
Source:
HEK293
2
2 Cited Publications
Cat. No.: HY-P7044G
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:
Human
Source:
E. coli
2
2 Cited Publications
Cat. No.: HY-P7044A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differentiation Factor; Interleukin BSF-2; Interleukin 6; Interferon Beta-2
Species:
Human
Source:
CHO
1
1 Cited Publications
Cat. No.: HY-P1415A
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
1
1 Cited Publications
Cat. No.: HY-P73101
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Hgf; Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor); Prev. DFNB39; Lung Fibroblast-Derived Mitogen; HPTA; Hepatopoietin-A; SF; Scatter Factor; F-TCF; Deafness, Autosomal Recessive 39; HgfB; Hepatopoietin A; Hepatocyte Growth Factor; Fibroblast-D
Species:
Rat
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P73928
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Hgf; Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor); Prev. DFNB39; Lung Fibroblast-Derived Mitogen; HPTA; Hepatopoietin-A; SF; Scatter Factor; F-TCF; Deafness, Autosomal Recessive 39; HgfB; Hepatopoietin A; Hepatocyte Growth Factor; Fibroblast-D
Species:
Mouse
Source:
HEK293
1
1
1 Cited Publications
Cat. No.: HY-P7378
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:
Mouse
Source:
CHO
1
1 Cited Publications
Cat. No.: HY-P7044B
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
